190 filings
6-K
ARGX
Argen X SE
9 May 24
On track to submit filing for pre-filled syringe (PFS) in second quarter 2024
7:06am
6-K
ARGX
Argen X SE
8 May 24
Current report (foreign)
6:15am
6-K
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
6-K
g70vr c0442d06t
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
6-K
y5f3a8q8xvtgkndidv
21 Mar 24
Current report (foreign)
6:07am
6-K
qik781w
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
omhr8x0l5b4dt8
29 Feb 24
Current report (foreign)
4:04pm
6-K
t0c d9qc2z8ahu
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
6-K
93bym1 fzdmjaau7
18 Jan 24
Current report (foreign)
6:10am
6-K
4ig7po
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
wfc iwyfoqaj
20 Dec 23
Current report (foreign)
6:00am
6-K
dkec5ke sb
28 Nov 23
Current report (foreign)
6:01am
6-K
5l6imd7vx8xd24i1f
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
zj63xfkc771pjbect2
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
7xjfv8
31 Oct 23
Current report (foreign)
9:14am
S-8
8y796u4mrw5zpck
27 Sep 23
Registration of securities for employees
4:42pm
6-K
ctwedm8 gzu1
21 Sep 23
Current report (foreign)
8:38am